Switching From Compounded Tirzepatide to Zepbound: Dose, Cost, Coverage

You can move from compounded tirzepatide to Zepbound, but it takes a new prescription for a different product, not a refill. Zepbound's label gives one recommended starting dose for every use, 2.5 mg once a week for 4 weeks, and it has no instructions for people switching from another product.¹ Lilly's own answer for people switching from another medicine repeats that starting dose and tells them to work out the right approach with their healthcare provider.² A compounded dose may not line up with a Zepbound dose, so your prescriber decides where you start; never use the two together.¹

If you want insurance to pay, be ready to meet a plan's rules for a first request. In the published criteria we read from CVS Caremark, Express Scripts and Prime Therapeutics, renewal depends on time on Zepbound itself or on the plan's own earlier approval, and none of them mentions compounded tirzepatide.^{3, 4, 5} Plans also differ on which weight counts as your starting weight, so keep a dated record of what you weighed before your first dose of any weight-loss medicine.^{3, 4, 6}

If you pay for Zepbound yourself, Lilly's direct-to-patient service, LillyDirect, charges $299 to $449 for a 28-day supply as of October 3, 2026, depending on the dose and on refilling on time.² What Zepbound costs has the tiers and the extras.

Compounded tirzepatide is made by a compounder, usually a pharmacy, not by Lilly. FDA has not approved it, and FDA does not check its safety, effectiveness or quality before it reaches buyers.⁷ Jump to what plans say about compounded use, safety checks for the switch or leaving a PlexusDx program.

How the switch from compounded tirzepatide to Zepbound works

Taking these steps in order helps you avoid a prescription you can't fill, or a break in treatment you didn't plan. Your prescriber may change the order for you.

1. Sort out payment before you stop. If you have insurance, ask your plan whether it covers Zepbound for your use, in which form, and whether it needs prior authorization (approval before the plan pays). If your prescription goes to LillyDirect, Lilly says it checks your coverage and supports you if prior authorization is required.² See how plans treat earlier compounded use and what Zepbound costs without coverage.
2. Get a Zepbound prescription. Zepbound is a prescription medicine, so your current prescriber or another licensed clinician has to write a new prescription for it.¹ To fill it at LillyDirect, Lilly asks you to have your doctor send it to LillyDirect Pharmacy.² If your current prescriber won't write it, LillyDirect also lists independent telehealth services for obesity care. Their providers decide for themselves whether a medicine is right for you, Lilly does not endorse them, and their fees are separate from the medicine's price.⁸ Our tirzepatide cost page shows the rates they reported on October 3, 2026.
3. Choose the form with your prescriber. LillyDirect sells Zepbound in three forms, and the form decides where you can buy it and who can pay (see the list below).
4. Let your prescriber set the first dose. What the label and Lilly say is in the next part, followed by why your compounded dose may not carry over. Go through the label's safety checks together before the first injection.
5. Don't overlap the two. Zepbound's label and Medication Guide say it should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicine.¹ That covers compounded tirzepatide and compounded semaglutide too. Ask your prescriber when to take your last compounded dose and your first Zepbound dose.
6. Learn the new device. The label tells prescribers to make sure you are trained on the specific form you are prescribed, and trained again if the form changes. Your provider should show you how to prepare your dose before your first injection.¹
7. Ask what to do with leftover compounded medicine. Don't keep it to use alongside Zepbound. FDA's advice is to throw out an opened multiple-dose vial once 28 days have passed since its first use, even if some medicine is left.⁹ Our page on pens and vials explains why leftover medicine is not an extra dose.

The three forms of Zepbound that LillyDirect sells, as of October 3, 2026:

• Single-dose pen: one weekly dose per pen, with the needle built in. Lilly's savings card for people with commercial insurance applies to this form when the plan covers it (terms under cost).^{2, 10}
• KwikPen: one pen that holds four weekly doses, with a new pen needle for each. LillyDirect sells it to people paying for themselves and lists "select insurance accepted," and it is the only form of Zepbound that Medicare's GLP-1 Bridge covers.^{2, 11} A KwikPen is for one person only: the Medication Guide warns that sharing it, or its needles, can spread a serious infection even when the needle is changed.¹
• Single-dose vial: one weekly dose per vial, drawn up with a new needle and syringe each time. Vials are sold only through LillyDirect, and only to people paying for themselves.^{1, 2}

What the label and Lilly say about your first dose

Zepbound's label recommends 2.5 mg once a week for the first 4 weeks, for every use. It says 2.5 mg is for starting treatment and is not an approved maintenance dose. The dose then rises in steps at least 4 weeks apart, a schedule the label says is meant to lower the risk of stomach and bowel side effects. For weight management, its maintenance doses are 5, 10 or 15 mg a week.¹

The label's dosing section covers starting, maintenance, a missed dose and how to inject. It has no instructions for anyone switching from compounded tirzepatide, another tirzepatide product or another GLP-1 drug.¹

Lilly's LillyDirect site does take up the question. Its answer to "I was on a different medication and want to switch to Zepbound. Which dose should I start on?" says the recommended starting dose is 2.5 mg, and that your healthcare provider may raise it in 2.5 mg steps, at least 4 weeks apart, until you reach the maintenance dose. It adds that if you are switching from another medication, you should talk to your provider about the right approach for you. It does not name compounded products.²

So the choice is your prescriber's. Ask how they picked your first dose and which side effects to watch for in the first weeks.

Why a compounded dose may not carry over

The dose on your compounded label doesn't tell you which Zepbound dose matches it, for several reasons:

• Concentrations and "units" vary. In a 2024 alert about compounded semaglutide injections, FDA said concentrations differ from one compounder to another, a single compounder may sell several, and directions may express a dose in "units," whose volume depends on the concentration, instead of milligrams or milliliters. Most of the error reports described people drawing up more than the prescribed dose from a multiple-dose vial, so that they took 5 to 20 times the intended dose; in others, prescribers' conversions from milligrams to units or milliliters led to 5 to 10 times the dose. Approved semaglutide injections, FDA noted, are dosed in milligrams at standard concentrations.¹² Our page on pens and vials covers how those mix-ups happen.
• FDA's concerns reach tirzepatide too. Other adverse-event reports reaching FDA may be related to doses of compounded semaglutide or tirzepatide beyond what the approved labels allow: more in one dose, more frequent doses or faster increases. Some of those events were serious, FDA says, and some people reported seeking medical attention for symptoms such as nausea, vomiting and abdominal pain. FDA asks prescribers to be vigilant in setting doses and dosing schedules for these products, and encourages patients to ask their provider or compounder how to measure and give the intended dose.⁹
• Strength can be off. FDA says poor compounding practices can produce a drug with too much or too little active ingredient.⁷
• Added ingredients and other forms. A 2026 article in The Annals of Pharmacotherapy describes a Google search of compounding websites in February and March 2025 for semaglutide and tirzepatide products that differed from the approved products in strength, route or formulation. It found 33 unique products. Of those, 48% paired the drug with another ingredient, such as vitamin B12 (cyanocobalamin), glycine, niacinamide, docusate or ondansetron, and all 17 products with a single active ingredient were sublingual (taken under the tongue) or tablets that dissolve in the mouth.¹³ Zepbound's ingredient list includes none of those added ingredients.¹ Our provider guide explains what added ingredients and non-injected forms change.
• Pills and drops have no approved match. Zepbound and Mounjaro are both injections given under the skin.^{1, 14} Lilly said in an open letter dated June 20, 2024 that FDA had approved tirzepatide only as an injection under the skin and that no regulator had evaluated oral or nasal forms.¹⁵

Even Lilly's own forms of Zepbound hold different volumes of liquid for the same dose, and the label calls for new training whenever your form changes.¹ A volume or unit count from a compounded vial says nothing reliable about a Zepbound dose, which is why this page gives no conversions.

What to bring to your prescriber

Lilly's sample letter of medical necessity, a template prescribers can adapt for insurers, asks for each past treatment's name, strength, form, start and stop dates, reason for stopping and result, along with your weight and body mass index (BMI) history.¹⁶ Gather the same details:

• Your pharmacy label, or a clear photo of it: the product name, strength in mg per mL, your dose in mg as well as any "units," added ingredients, the form and the pharmacy's name. FDA suggests contacting the compounder, or the telehealth company you bought it through, with questions about the label.⁹
• The date you started, each dose change and the date of your last dose.
• Side effects you had, especially after dose increases.
• Your weight and BMI before your first dose of any weight-loss medicine, with the date, and your weight now. Plans may ask for either (see insurance).
• Your other medicines, especially insulin or a sulfonylurea (a type of diabetes medicine), birth control pills, and pills such as warfarin whose levels need watching.¹

Are compounded tirzepatide and Zepbound the same medicine?

No. Zepbound is Lilly's FDA-approved medicine; compounded tirzepatide is made by a compounder, and FDA has not approved it.^{1, 7} Zepbound and Mounjaro are Lilly's brand names for its two FDA-approved tirzepatide injections, which are approved for different uses.^{1, 14} There is no compounded Zepbound: products sold as compounded tirzepatide come from compounders, not from Lilly.

FDA's position is plain. It does not approve compounded drugs, and it does not confirm that they are safe, effective or of good quality before they go on the market. They are not generics either: a generic must win FDA approval, which includes showing therapeutic equivalence to its brand.⁷ FDA tells telehealth companies not to describe a compounded drug as a generic or as the same as an FDA-approved drug, or as proven to produce the same result.¹⁷

Is it as effective as Zepbound, or is Zepbound stronger? Published evidence can't say. The results on Zepbound's label come from trials of Zepbound.¹

On October 4, 2026, a search of PubMed, the National Library of Medicine's research index, for "compounded" and "tirzepatide" in titles and abstracts found no record indexed as a clinical trial or a randomized controlled trial.¹⁸ A practice group of the American College of Clinical Pharmacy says only limited data, from small groups of patients, show good results with compounded semaglutide and tirzepatide.¹⁹ The American Diabetes Association recommends against compounded GLP-1 and dual GIP/GLP-1 products, citing uncertainty about what they contain and about their safety, quality and effectiveness.²⁰

On safety, FDA had received more than 730 reports of adverse events associated with compounded tirzepatide as of May 31, 2026, and it says many of the adverse events reported for compounded products appear to be consistent with those reported for the FDA-approved drugs. Federal law does not require compounding pharmacies other than outsourcing facilities to send FDA these reports, so FDA expects the true count is higher, and it notes that a report does not always show the drug caused the problem.⁹

FDA's recommendation is an FDA-approved drug whenever one is available and right for the patient. It says a compounded drug might be appropriate if your medical needs can't be met by an approved drug or the approved drug isn't available.²¹ The pharmacists' group adds that, whenever possible, providers should help patients get approved medicines.¹⁹

Will a plan count your time on compounded tirzepatide?

Coverage is set by your plan, and some plans leave weight-loss drugs out; Medicare's basic Part D benefit does, unless a plan adds them.²² The criteria below apply only if your plan covers Zepbound for your use, and our guide shows how to find out whether your plan covers it at all.

None of the published criteria we read on October 3, 2026 counts earlier compounded use, or even mentions it. CVS Caremark, Express Scripts and Prime Therapeutics post the rules their reviewers use for Zepbound, and in each set, keeping coverage runs through time on Zepbound itself or through the plan's own earlier approval.^{3, 4, 5} These are three companies' documents, not every plan's rules; our prior authorization guide sets out each one's renewal terms. Lilly's prior authorization guide for prescribers frames continuation the same way: request it if the patient has already received Zepbound.²³

So ask your plan which criteria it will use for you, and be ready to meet the first-time ones. Caremark's, for example, call for at least 6 months in a weight-management program with follow-up before drug therapy, and a starting BMI of at least 30, or 27 or more alongside a weight-related condition.³ Prime's first-time criteria add that if you tried a weight-loss drug in the past 12 months, your prescriber must expect a repeat course to work, and every example it gives is a brand name.⁵ Our guide also compares the plans' first-time criteria.

Which weight counts as your starting weight. The documents don't agree:

• When a patient is moving from another weight-loss drug, Caremark's note asks reviewers to consider the patient's BMI at the start of any drug therapy.³
• Express Scripts uses BMI from before any GLP-1 or GLP-1/GIP drug, naming Saxenda, Wegovy and Zepbound as examples.⁴
• Evernorth's EncircleRx program, on plans that add it, takes the BMI at your first coverage review as the one that counts if you already take a GLP-1.⁶
• For Medicare's GLP-1 Bridge, CMS says its criteria must have been met when GLP-1 therapy began, even if that was before you joined Part D.²⁴
• At renewal, Prime measures weight loss from before the requested drug was started.⁵

None of these says whether starting compounded tirzepatide counts as starting drug therapy or a GLP-1. Keep dated records of your weight before your first compounded dose and when you ask for Zepbound, give your plan accurate information, and ask which weight it uses. If treatment has already lowered your BMI, see what changes when your BMI falls on treatment.

The form on the prescription matters. Caremark's criteria leave Zepbound vials to Lilly's LillyDirect program, and Express Scripts' 2027 National Preferred Formulary, its prescription drug list, excludes Zepbound KwikPens and vials while listing single-dose pens among the preferred alternatives.^{3, 25} Ask which form your plan covers before your prescriber writes the prescription.

Medicare. CMS's Medicare GLP-1 Bridge, a temporary program running from July 1, 2026 to December 31, 2027, covers the Zepbound KwikPen for weight management, with a $50 copay for each one-month supply. It is for people with Part D who meet its criteria and get prior authorization, and it excludes anyone already receiving GLP-1 coverage from their Part D plan.^{11, 24} Our UnitedHealthcare page explains the Bridge's criteria and exclusions.

If the plan says no. Start with the reason and the deadline in the denial letter. Under the rules HealthCare.gov describes, you have 180 days from a denial notice to file an internal appeal; a Medicare drug plan allows 65 days from the date printed on the notice, though a Part D appeal cannot win weight-loss coverage that the plan's benefits leave out.^{22, 26, 27, 28} Bridge decisions can't be appealed, but a prescriber can resubmit with corrected or new information.²⁴ Our guide walks through each appeal step and covers what to do if coverage is out of reach.

Medicaid, TRICARE or the VA. Start with our pages on Medicaid coverage of GLP-1 drugs and on TRICARE and VA coverage.

What Zepbound costs if you pay yourself

Because the label starts everyone at 2.5 mg, your first 28-day supply is the cheapest. As of October 3, 2026, LillyDirect sells it, in vials or a KwikPen, for $299. The price rises with the dose, to $449 at 7.5 mg and above if each refill comes within 45 days of receiving the last one; a later refill at those doses costs $499 to $699.^{2, 10} Needles and syringes are extra. The KwikPen's prices come through a separate Lilly self-pay card, which has its own limits and ends December 31, 2026.¹⁰

If a commercial plan covers single-dose pens, Lilly's savings card may lower what you pay there. As of October 3, 2026, it excludes anyone in a government program, including Medicare, Medicaid, TRICARE and the VA, and it ends December 31, 2026.¹⁰ Our cost guide shows which of Lilly's offers fit your coverage and every GLP-1 brand's cash price, and our tirzepatide cost page lists each dose's LillyDirect price and totals a full year of Zepbound fills.

Gaps, missed doses and restarting

A gap can open while you wait for a coverage decision or a delivery. Zepbound's label has one rule for missed doses, and it covers a single late dose: take it within 4 days (96 hours), and if more time has passed, skip it and wait for your regular day.¹ It has no rule for restarting after weeks without tirzepatide, so if your switch involves a break, your prescriber decides how you restart.¹

The label doesn't describe restarting, but its figures on starting are worth knowing. In Zepbound's two main weight-loss trials, stomach and bowel side effects affected 56% of people at each dose and 30% on placebo, and nausea, vomiting and diarrhea mostly happened while the dose was being increased, becoming less frequent over time.¹

The label also tells prescribers to watch kidney function in people with side effects that could dehydrate them, especially when starting Zepbound or raising the dose. If nausea, vomiting or diarrhea won't stop, the Medication Guide says to tell your provider right away, and to keep drinking fluids to lower the chance of dehydration.¹

Longer breaks carry another cost. In the label's withdrawal trial, adults without type 2 diabetes who had obesity or were overweight with at least one weight-related condition took Zepbound for 36 weeks, escalated to their maximum tolerated dose of 10 or 15 mg; over the next 52 weeks, weight rose 14.0% on average in those switched to placebo and fell a further 5.5% in those who stayed on Zepbound.¹ That was a year off treatment, not a few weeks, but it is a reason to plan the move before your last compounded dose; our page on how weight changes over time on tirzepatide has more.

Safety checks for the switch to Zepbound

Zepbound has a label and Medication Guide of its own, and both apply to you even after months on compounded tirzepatide. This section covers what a switch makes most pressing, not every risk, so read both documents and ask your prescriber how each point fits you.¹ The urgent signs come first.

Act right away on any of these:

• Severe stomach pain that won't ease, with or without nausea or vomiting. Stop taking Zepbound and call your prescriber right away. The pain may reach your back, and it can be a sign of pancreatitis, inflammation of the pancreas, which in its severe forms has been fatal.¹
• Signs of a serious allergic reaction, including anaphylaxis or angioedema (swelling under the skin). Stop Zepbound and get medical help right away if you have any of these:¹
  • difficulty breathing or swallowing
  • swelling in the face, lips, tongue or throat
  • a severe rash or itching
  • a very fast heartbeat
  • fainting or feeling dizzy
• Taking too much. Contact Poison Help at 1-800-222-1222 or your prescriber, or go straight to the nearest emergency room.¹

Whether it is approved for you. Zepbound is FDA-approved for adults who have obesity, or overweight together with at least one weight-related condition, to reduce excess weight and maintain the loss long term, as part of a reduced-calorie diet and increased physical activity. Its other approval is for moderate to severe obstructive sleep apnea in adults with obesity.¹ In the main trial behind the weight approval, people counted as having obesity at a BMI of 30 or more, and as overweight at a BMI of 27 up to 30 if they also had a condition such as sleep apnea, high blood pressure, cardiovascular disease or abnormal cholesterol.¹

Zepbound's safety and effectiveness have not been established in children, so use under 18 would be off-label (used in a way the label does not approve), as would any use outside those approvals.¹ If you are under 18, or your weight and health fall outside those approvals, talk with your own doctor about whether any GLP-1 drug fits you, and see our page on GLP-1s if you don't have obesity or overweight.

Who must not use it. Zepbound's boxed warning exists because tirzepatide led to thyroid C-cell tumors in rats; it is not known whether it does so in people, including medullary thyroid carcinoma (MTC), a thyroid cancer. It is not for people with a personal or family history of MTC or with multiple endocrine neoplasia syndrome type 2 (MEN 2), or for people who have ever had a serious allergic reaction to tirzepatide or another ingredient in Zepbound. Its label also advises against it in severe gastroparesis, when the stomach empties far too slowly.¹

What was in your compounded product, and what is in Zepbound. The KwikPen contains benzyl alcohol, glycerin and phenol, which Zepbound's single-dose pens and single-dose vials do not.¹ Your compounded product was made with its own ingredients, so tell your prescriber what its label listed and about any reaction you had to it.

Pregnancy and breastfeeding. Zepbound's label warns that it may harm an unborn baby and tells you to stop it once you know you are pregnant. Zepbound may also pass into breast milk, so if you breastfeed, ask your provider how best to feed your baby.¹

Other medicines and procedures. Taking insulin or a sulfonylurea with Zepbound raises the chance of low blood sugar, and the label reports it even in adults free of type 2 diabetes. Because Zepbound slows stomach emptying, it can change how pills you swallow are absorbed; the label names warfarin as one drug to monitor.¹ Tell every doctor and dentist involved in a planned surgery or procedure with anesthesia or deep sedation that you use Zepbound: in rare cases, food or liquid has entered the lungs of people on GLP-1 drugs during these procedures.¹

The first weeks on Zepbound. If you take birth control pills, the label recommends switching to a non-oral method of birth control, or adding a barrier method, for the 4 weeks after your first Zepbound dose and the 4 weeks after each dose increase; it doesn't say whether earlier compounded use changes that, so ask your prescriber.¹ These weeks are also when the stomach side effects and fluid loss described under gaps and restarting are most likely. Stomach problems can be severe, so report any that are severe or lasting to your prescriber, and fluid loss can harm the kidneys; some reported cases needed dialysis.¹

Tell your prescriber about these at any point:

• Gallbladder disease happens more often with Zepbound and other GLP-1 drugs, so call your prescriber right away if you have fever, pain in the upper stomach, clay-colored stools, or yellowing skin or eyes.¹
• A possible thyroid tumor: shortness of breath, trouble swallowing, hoarseness, or a lump or swelling in your neck.¹
• Your eyes, if you have type 2 diabetes: tell your prescriber about any change in your vision.¹ The label reports temporary worsening of diabetic retinopathy (diabetes-related eye damage) with rapid improvement in blood sugar, and says people with a history of retinopathy should be monitored.¹
• Low blood sugar: sweating, shakiness, confusion, dizziness or a fast heartbeat.¹

Other switches people ask about

From Zepbound to compounded tirzepatide

That move runs against FDA's recommendation above. Now that the tirzepatide shortage is over (FDA confirmed it on December 19, 2024), a compounded product that copies an approved drug such as Zepbound generally needs the prescriber to determine and document a change that produces a significant difference for you, compared with Zepbound.²⁹ Under FDA's guidance, a lower price doesn't count, and a prescription that names only you and the formula doesn't show that decision.³⁰ FDA's general examples of when compounding fits are a patient allergic to a dye in an approved drug, or one who can't swallow a tablet and needs a liquid.⁷

Our provider guide explains what lawful compounded tirzepatide looks like, and our page on whether your doctor can prescribe it covers what the prescription has to show. If a prescriber does make this change, the dose cautions on this page apply in the other direction too, and so do the safety checks, since FDA says many of the events reported for compounded products appear to be consistent with those reported for the approved drugs.⁹

To or from Mounjaro

Mounjaro is Lilly's other tirzepatide brand. With diet and exercise, it is approved for blood sugar control in adults and in children 10 and older who have type 2 diabetes. It is also approved to lower the chance of major cardiovascular events (a heart attack, a stroke or cardiovascular death) in adults with type 2 diabetes whose risk of those events is high. Weight loss is not one of its approved uses, so taking it only for weight loss would be off-label.¹⁴

LillyDirect lists a self-pay price for Mounjaro from $499 a month, but only for a prescription written for an approved use (as of October 3, 2026).^{31, 32} Its label carries Zepbound's boxed warning on thyroid C-cell tumors and rules it out for the same people: those with a personal or family history of MTC, those with MEN 2 and those who have had a serious allergic reaction to tirzepatide or another of its ingredients. It is not recommended with severe gastroparesis, its birth-control-pill advice matches Zepbound's, and its other warnings cover pancreatitis, low blood sugar with insulin or a sulfonylurea, serious allergic reactions, kidney injury from dehydration, severe stomach problems, diabetic eye complications, gallbladder disease and aspiration during anesthesia.¹⁴

On pregnancy, Mounjaro's label also warns, based on animal studies, that it may harm an unborn baby, but its advice differs from Zepbound's stop rule: it says Mounjaro should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.¹⁴ So if you become pregnant while taking it, contact your prescriber right away to decide together whether to continue.

Never use Mounjaro and Zepbound together.¹ If you have type 2 diabetes, ask the clinician who treats it which drug fits you.

From semaglutide, Saxenda or another GLP-1 drug

Lilly's switching answer covers anyone on "a different medication": the 2.5 mg recommended starting dose, and a talk with your provider about the right approach.² Zepbound's label gives no instructions for switching from another GLP-1 drug, and its rule against combining covers any GLP-1 receptor agonist, compounded semaglutide included.¹ Bring the records listed above.

From one compounded provider to another

A new provider means a new prescriber and often a different pharmacy. FDA's 2024 alert about compounded semaglutide noted that concentrations vary from one compounder to another, so ask any new compounder for the strength of its tirzepatide in mg per mL.¹² The dose questions on this page apply here too. Bring your records, make sure the new prescriber knows the date of your last dose, and never use products from two sellers at the same time. Our provider guide lists checks to run before you pay.

Leaving a PlexusDx program for Zepbound

PlexusDx publishes this page and offers compounded GLP-1 plans, and everything above applies to them. Its terms below are as of October 19, 2026.

What you have been taking. Like all compounded tirzepatide, the tirzepatide you get through PlexusDx is not FDA-approved, and the reasons a compounded dose may not carry over apply to it. PlexusDx's Terms of Service say that formulations and added ingredients may vary by pharmacy and fill, so the label on your own prescription is the record to bring. What you took was either a weekly injection or an orally disintegrating tablet (ODT) used daily. If it was an injection from PlexusDx's current catalog, it contained vitamin B12 or glycine as well; people in California choose between them in the intake, while for others the pharmacy decides and checkout does not show it, so the label or the pharmacy will tell you which you had. Lone Star says any part of the prescriber's reasoning that relies on the add-in has to fit the patient's clinical needs. Ingredient lists for the tablets haven't been published. No tirzepatide tablet is FDA-approved. A Microdose injection from the current catalog, which also has B12, uses weekly tirzepatide doses between 0.5 mg and 1.5 mg. Allergies reported in the intake go to the physician for a decision; tell your Zepbound prescriber about any reaction to B12 or glycine, which the intake's allergy checklist did not name.

PlexusDx's Microdose GLP-1 plan uses lower doses of compounded tirzepatide or semaglutide, and that is off-label: Zepbound's label treats 2.5 mg a week as a starting dose only and lists 5, 10 or 15 mg weekly as the doses for staying on treatment for weight.¹

Why compounded rather than Zepbound. Lone Star Virtual Health says the reason is individual: the prescribing physician documents why compounded tirzepatide was a better fit than Zepbound for that patient, explains it, and notes that compounded medicines lack FDA approval; added B12, B6 or glycine counts toward it only when the patient's clinical needs support that. Ask what was recorded for you, and if it no longer applies, raise that when you discuss switching.

Who prescribes. PlexusDx does not practice medicine. The clinicians come from Lone Star Virtual Health, PlexusDx's provider team, and they make the medical decisions, from whether to prescribe to dose changes and whether to continue or stop treatment; licensed partner pharmacies fill the prescriptions. Our provider guide applies its prescriber and pharmacy checks to PlexusDx.

A Zepbound prescription. PlexusDx does not sell or ship Zepbound or any other brand-name medication. If you would rather take Zepbound, an FDA-approved medicine, your provider may write a prescription you can fill at the pharmacy of your choice.

Insurance. PlexusDx is self-pay and does not bill health insurance. Unless your health plan approved Zepbound for you before, expect it to apply its first-time criteria, described above.

Stopping your PlexusDx plan. Look up your next renewal date before you plan your last compounded dose. Under PlexusDx's Refund & Cancellation Policy and Terms of Service:

• You can cancel or pause future renewals in PlexusDx's self-service portal at any time before the next renewal charge is processed; send any email or support request at least 3 business days ahead of the renewal.
• Pausing freezes future billing, fulfillment, remaining prepaid treatment time and the renewal clock while keeping your existing plan price, with no fixed maximum pause. Resuming may require a clinical reassessment.
• Cancelling a prepaid 3-, 6- or 12-month plan stops the next renewal, but it "does not create a prorated refund of the current prepaid term" (a refund for the part of the term you have not used). Already-paid treatment remains available through the term, subject to continued clinical appropriateness.
• If treatment has been approved but the prescription has not yet been sent to the dispensing pharmacy, you may request cancellation and a full refund; once it has been sent, it generally cannot be cancelled or refunded merely because you changed your mind, cancelled or paused. If your clinician ends treatment for a medical reason, PlexusDx refunds unused, not-yet-dispensed prepaid months at the monthly-equivalent rate you paid.
• For an approved switch to another treatment, unused prepaid value becomes a dollar credit toward the new treatment. A Zepbound prescription goes to the pharmacy you choose, so email support@plexusdx.com before you cancel and ask how your unused months would be handled.

Our program comparison shows how these terms compare with other programs'. Before you stop, ask for your dose history and the details on your pharmacy label, so your new prescriber has them.

Sources

1. ZEPBOUND (tirzepatide) injection: prescribing information and Medication Guide (revised August 2026), Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 3, 2026.
2. Authentic Zepbound (tirzepatide) Shipped to You | LillyDirect, Eli Lilly and Company, accessed October 3, 2026.
3. Initial Prior Authorization with Quantity Limit: Zepbound Weight Loss Management (criteria 6192-C), CVS Caremark, accessed October 3, 2026.
4. Weight Loss: Glucagon-Like Peptide-1 Agonists Prior Authorization Policy (revised April 15, 2026), Express Scripts, accessed October 3, 2026.
5. Weight Management Prior Authorization with Quantity Limit Program Summary (Commercial, effective July 1, 2026), Prime Therapeutics, accessed October 3, 2026.
6. Provider information on our GLP-1 program (EncircleRx), Evernorth Health Services, accessed October 3, 2026.
7. Compounding and the FDA: Questions and Answers, U.S. Food and Drug Administration, content current as of September 16, 2025, accessed October 3, 2026.
8. Online Pharmacy Service Options for Select Lilly Medicines | LillyDirect (Find telehealth care section), Eli Lilly and Company, accessed October 3, 2026.
9. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration, content current as of October 1, 2026, accessed October 3, 2026.
10. Zepbound (tirzepatide): Full Terms and Conditions, Eli Lilly and Company, accessed October 3, 2026.
11. Weight loss drugs, Medicare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
12. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (July 26, 2024), U.S. Food and Drug Administration, accessed October 3, 2026.
13. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown, Belcourt J, Sapowadia A, White CM, The Annals of Pharmacotherapy, 2026, accessed October 3, 2026.
14. MOUNJARO (tirzepatide) injection: prescribing information (revised August 2026), Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 3, 2026.
15. An Open Letter From Eli Lilly and Company Regarding Certain Practices Related to Mounjaro and Zepbound (June 20, 2024), Eli Lilly and Company, accessed October 3, 2026.
16. Sample Letter of Medical Necessity (Zepbound), Eli Lilly and Company, accessed October 3, 2026.
17. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs, U.S. Food and Drug Administration, content current as of June 15, 2026, accessed October 3, 2026.
18. PubMed search: compounded[tiab] AND tirzepatide[tiab], clinical trial and randomized controlled trial filters, National Library of Medicine, accessed October 4, 2026.
19. Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy, Courtney LA, et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2025, accessed October 3, 2026.
20. The American Diabetes Association Announces Statement on Compounded Incretin Products (December 2, 2024), American Diabetes Association, accessed October 3, 2026.
21. Compounding when Drugs are on FDA's Drug Shortages List, U.S. Food and Drug Administration, accessed October 3, 2026.
22. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements (Rev. 18), Centers for Medicare & Medicaid Services, accessed October 3, 2026.
23. Zepbound Prior Authorization Resource Guide, Eli Lilly and Company, accessed October 3, 2026.
24. Medicare GLP-1 Bridge: Information for Providers, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
25. 2027 National Preferred Formulary Exclusions, Express Scripts, accessed October 3, 2026.
26. Internal appeals, HealthCare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
27. Appeals in a Medicare drug plan, Medicare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
28. 42 CFR 423.578, Exceptions process, Electronic Code of Federal Regulations, via the Legal Information Institute, Cornell Law School, accessed October 3, 2026.
29. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S. Food and Drug Administration, content current as of April 1, 2026, accessed October 3, 2026.
30. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry (January 2018), U.S. Food and Drug Administration, accessed October 3, 2026.
31. Authentic Mounjaro (tirzepatide) Shipped to You | LillyDirect, Eli Lilly and Company, accessed October 3, 2026.
32. Mounjaro (tirzepatide): LillyDirect Pharmacy Self Pay Purchase Offer Terms, Eli Lilly and Company, accessed October 3, 2026.

How we made this page

Someone moving from compounded tirzepatide to Zepbound has to piece the answer together from documents never written for them: a drug label, a manufacturer's FAQ, pharmacy benefit managers' coverage criteria and FDA alerts about compounded products. On October 3, 2026, we used AI tools to read those documents side by side, to note what each one says and leaves unsaid about a person arriving from a compounded product, and to draft the page from those notes. The sources that carried the most weight were the Zepbound and Mounjaro labels revised in August 2026, Lilly's LillyDirect page with its answer for people switching from another medicine, Lilly's prior authorization guide and sample letter, FDA's pages on compounded GLP-1 drugs and dosing errors, the Zepbound criteria from CVS Caremark, Express Scripts and Prime Therapeutics, Evernorth's EncircleRx page, CMS's Medicare GLP-1 Bridge guidance and a PubMed search for records of trials of compounded tirzepatide.

Neither the label nor Lilly gives a rule for converting a compounded dose, so the page quotes their starting instruction and offers no conversion of its own. Each fact taken from a source links to that source, with the supporting passage recorded word for word in our evidence file; software compared those passages with the copies of the labels, plan documents, Lilly pages and other sources we saved on October 3 and 4, and AI reviewers read the draft against the sources themselves. Those checks catch statements that drift from their sources, but they are no substitute for review by a doctor or a lawyer. We did not use or test any product for this page, and we did not interview prescribers, pharmacists or insurers.

PlexusDx's terms in the last section are statements by the company itself, current as of October 19, 2026, so they link to its published policies rather than carrying source numbers. The older post at this address said compounded tirzepatide and Zepbound had identical ingredients and equal results and safety, quoted brand prices we could not trace and promoted a genetic test; we kept none of its text or claims.

Jay Hastings approved this version on October 19, 2026 after reviewing it. Dr. Asad K. Niazi, MD, MPH, reviewed the medical content on October 17, 2026. He is co-founder and CEO of Lone Star Virtual Health, the company that provides PlexusDx's prescribing clinicians, so he has a business relationship with PlexusDx. PlexusDx sells compounded GLP-1 treatment, so we have a financial interest in this topic. How we write, check and correct pages is set out in our editorial policy.